Loading
ASC40 is an experimental small-molecule drug from Ascletis Pharmaceuticals in phase 3 trials for glioma & glioblastoma, with its target not yet stated publicly.
ASC40 (TVB-2640) is a small-molecule drug developed by Ascletis Pharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: ASC40 tablets administered orally once daily. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05118776 (Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM), in glioma & glioblastoma. The largest, NCT05118776, plans to enrol 136 participants (actual) with primary completion was scheduled for 2025-06 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.ASC40 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ASC40" OR ABSTRACT:"ASC40" OR TITLE:"TVB-2640" OR ABSTRACT:"TVB-2640") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ASC40, not a curated reading list.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.